Abstract
Liver X receptors (LXRs) are members of the nuclear hormone receptor superfamily of ligandactivated transcription factors. Two LXRs (LXRa and LXRb) were initially characterized as orphan members of this superfamily with disparate patterns of tissue expression. These two receptors later were recognized as sterol-responsive with the ability to directly bind several oxysterol metabolites. Many LXR target genes have been identified that implicate these receptors in a variety of physiological processes including cholesterol transport and metabolism, glucose metabolism, and inflammation. Synthetic LXR ligands have been designed with the potential to treat disorders such as atherosclerosis and diabetes. In this review, we describe the potential utility of LXR ligands in the treatment of disease.
Keywords: nuclear receptor, steroid, hdl, ldl, transcription, heart disease, diabetes, inflammation
Mini-Reviews in Medicinal Chemistry
Title: The Pharmacology of LXR
Volume: 5 Issue: 8
Author(s): Laura F. Michael, Jeffrey M. Schkeryantz and Thomas P. Burris
Affiliation:
Keywords: nuclear receptor, steroid, hdl, ldl, transcription, heart disease, diabetes, inflammation
Abstract: Liver X receptors (LXRs) are members of the nuclear hormone receptor superfamily of ligandactivated transcription factors. Two LXRs (LXRa and LXRb) were initially characterized as orphan members of this superfamily with disparate patterns of tissue expression. These two receptors later were recognized as sterol-responsive with the ability to directly bind several oxysterol metabolites. Many LXR target genes have been identified that implicate these receptors in a variety of physiological processes including cholesterol transport and metabolism, glucose metabolism, and inflammation. Synthetic LXR ligands have been designed with the potential to treat disorders such as atherosclerosis and diabetes. In this review, we describe the potential utility of LXR ligands in the treatment of disease.
Export Options
About this article
Cite this article as:
Michael F. Laura, Schkeryantz M. Jeffrey and Burris P. Thomas, The Pharmacology of LXR, Mini-Reviews in Medicinal Chemistry 2005; 5 (8) . https://dx.doi.org/10.2174/1389557054553767
DOI https://dx.doi.org/10.2174/1389557054553767 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiovascular disease management through restrained inflammatory responses
Current Pharmaceutical Design Coronary Pressure Measurement Based Decision Making for Percutaneous Coronary Intervention
Current Cardiology Reviews Novel Concepts in the Pathogenesis and Management of Pediatric Hypertension
Current Pediatric Reviews Gender as a Regulator of Atherosclerosis in Murine Models
Current Drug Targets Protocatechuic Acid and Human Disease Prevention: Biological Activities and Molecular Mechanisms
Current Medicinal Chemistry Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology Sunlight Vitamin D and Skin Cancer
Anti-Cancer Agents in Medicinal Chemistry Research on the Pathological Mechanism and Drug Treatment Mechanism of Depression
Current Neuropharmacology Recent Progress of Medicinal Chemistry Research on Peroxisome Proliferator-Activated Receptor (PPAR) Ligands for the Treatment of Metabolic Syndrome
Current Bioactive Compounds Lipids in the Diet and the Fatty Acid Profile in Beef: A Review and Recent Patents on the Topic
Recent Patents on Food, Nutrition & Agriculture Pharmacogenomics: A Tool to Prevent and Cure Coronary Heart Disease
Current Pharmaceutical Design Complications of Diabetes: An Insight into Genetic Polymorphism and Role of Insulin
Recent Patents on Inflammation & Allergy Drug Discovery Fabry Disease Cardiomyopathy: from Genes to Clinical Manifestations
Current Pharmaceutical Biotechnology Metabolic Obesity: The Paradox Between Visceral and Subcutaneous Fat
Current Diabetes Reviews Novel Strategies for the Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Immune System Alterations by Aldosterone During Hypertension: From Clinical Observations to Genomic and Non-Genomic Mechanisms Leading to Vascular Damage
Current Molecular Medicine Omentin: Linking Metabolic Syndrome and Cardiovascular Disease
Current Vascular Pharmacology Cardioprotection Acquired Through Exercise: The Role of Ischemic Preconditioning
Current Cardiology Reviews Tissue Protective and Anti-Fibrotic Actions of Suramin: New Uses of an Old Drug
Current Clinical Pharmacology MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets